Hemostemix Competitors and Similar CompaniesClear all

Hemostemix's competitors and similar companies include Alliance Pharma, Unither Pharmaceuticals, Aurobindo Pharma and Glenmark Pharmaceuticals.

	Hemostemix Hemostemix is a biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.	Alliance Pharma Alliance is an international pharmaceutical company.	Unither Pharmaceuticals Unither Pharmaceuticals is a company that engages in sterile unit-doses contract manufacturing.	Aurobindo Pharma Aurobindo Pharma, a pharmaceutical company, manufactures and sells generic medicines to public and private health sectors in South Africa.	Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a pharmaceutical company that develops and markets branded and generic formulations.
Founding Date	Founding Date 2006	Founding Date 1996	Founding Date 1993	Founding Date 1986	Founding Date 1977
Type	Type Public	Type Private	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech pharma
Locations	Locations Calgary, CA HQ	Locations Wiltshire, GB HQ Paris, FR Düsseldorf, DE Milano, IT Singapore, SG Tres Cantos, ES see more	Locations Amiens, FR HQ Wuhan Shi, CN Colomiers, FR Coutances, FR Gannat, FR see more	Locations Hyderabad, IN HQ Hyderabad, IN South Brunswick Township, US	Locations Mumbai, IN HQ Mumbai, IN
Employees	Employees N/A	Employees 290	Employees 1,4801% increase	Employees 26,015	Employees 14,989
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) £178.8m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) ₹333.8b (FY, 2026)	Revenue (est.) ₹131.5b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods £68.2m (FY, 2024)	Cost of goods N/A	Cost of goods ₹134.9b (FY, 2026)	Cost of goods ₹46.7b (FY, 2025)
Gross profit	Gross profit $1.6m (FY, 2025)	Gross profit £110.6m (FY, 2024)	Gross profit N/A	Gross profit ₹206.6b (FY, 2026)	Gross profit ₹87b (FY, 2025)
Net income	Net income ($4.7m) (FY, 2025)	Net income (£10.7m) (FY, 2024)	Net income N/A	Net income ₹35b (FY, 2026)	Net income ₹10.5b (FY, 2025)